Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 + HLX10 plus chemotherapy as first-line treatment in extensive-stage small cell lung cancer
CTR20220668Phase 2Terminated
- Sponsor
- HyBioPharma
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pimurutamab and serplulimab in small cell lung cancer (SCLC), sponsored by HyBioPharma. Primary endpoints: Objective response rate (ORR) and Progression-free survival (PFS). Started Mar 2022; status: terminated.
02
Drugs
pimurutamabserplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20220668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220668.